Compare
Regencell Bioscience Holdings Ltd vs Target Group Inc. vs TFA Therapeutics, Inc. vs Functional Brands Inc.
| Latest fiscal year | Regencell Bioscience Holdings Ltd RGC | Target Group Inc. CBDY | TFA Therapeutics, Inc. RAJAF | Functional Brands Inc. MEHA |
|---|---|---|---|---|
| Year ended | 2025-06-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $3.88M | $1.25M | $6.61M |
| Revenue growth (YoY) | n/a | -41.1% | -0.6% | +0.7% |
| Gross margin | n/a | 53.3% | 61.1% | 52.7% |
| Operating margin | n/a | n/a | -11.3% | -21.2% |
| Net margin | n/a | -35.0% | -12.4% | 11.5% |
| Net income | -$3.58M | -$1.36M | -$154.8K | $758.5K |
| EPS (Diluted) | -$0.72 | $0.00 | $0.00 | $0.01 |
| Operating cash flow | -$3.11M | -$842.4K | -$35.8K | -$1.27M |
| Free cash flow | -$3.27M | n/a | n/a | -$1.28M |
| Cash & equivalents | n/a | n/a | $3.2K | $2.73M |
| Total assets | $5.76M | $6.18M | $4.66M | $9.11M |
| Total liabilities | $895.3K | $14.24M | $5.19M | $7.57M |
| Shareholders' equity | $4.86M | -$8.06M | -$534.6K | $1.54M |
| Return on year-end equity | -73.7% | n/a | n/a | 49.2% |
| Shares outstanding | 494.49M | 617.03M | 111.12M | 18.70M |
Revenue, most recent five fiscal years
| Fiscal year | Regencell Bioscience Holdings Ltd | Target Group Inc. | TFA Therapeutics, Inc. | Functional Brands Inc. |
|---|---|---|---|---|
| Latest | n/a | $3.88M Ended 2025-12-31 | $1.25M Ended 2025-12-31 | $6.61M Ended 2025-12-31 |
| 1 year earlier | n/a | $6.59M Ended 2024-12-31 | $1.25M Ended 2024-12-31 | $6.57M Ended 2024-12-31 |
| 2 years earlier | n/a | $3.72M Ended 2023-12-31 | $882.5K Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | $0 Ended 2022-12-31 | $53.3K Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $0 Ended 2021-12-31 | $879.3K Ended 2021-12-31 | n/a |